The need for preventive therapy in primary headaches

Bibliographic Details
Main Author: Peres, Mario Fernando Prieto
Publication Date: 2011
Other Authors: Amado, Daniel Krempel, Gonçalves, André Leite, Ribeiro, Reinaldo, Pagura, Jorge Roberto, Queiroz, Luiz Paulo de
Format: Article
Language: eng
Source: Revista Headache Medicine (Online)
Download full: https://headachemedicine.com.br/index.php/hm/article/view/78
Summary: Introduction: Primary headaches are common conditions. In Brazil, the prevalence of migraine is 15.2%, tension-type headache 13% and chronic daily headache (CDH) 6.9%. Although frequent disorders a proportion of patients are undertreated. Patients patterns of headache care can trend toward acute medication only and those in need of prevention may not receive it. Objective: To estimate the rates of preventive treatment in primary headache sufferers. Methods: A telephone interview containing questions about headache and socio-demographic characteristics was applied to 3,848 people from 27 States of Brazil, in its five geographical regions. We considered MIDAS > 10 points as a marker for the need of preventive treatment. Patients were asked if they were taking any medication on a daily basis or any treatment to prevent headaches from happening. Subjects were divided into: 1. Those who responded positively for the question regarding preventive treatment regardless of the treatment type. 2. Those who responded positively for the question, but only medications or treatments studied for migraine prevention, labeled as "Correct treatment" 3. Those who responded positively for the question, but only medications or treatments from the prevention consensus (Brazilian Headache Society), labeled as "Consensus treatment" Results: In total, 12.8% of primary headache sufferers had MIDAS higher than 10, meeting criteria for prophylactic treatment, but only 8.4% of them reported it, 3.9% were using a right preventive treatment. The percentage of patients in need for prevention was 24.7% in migraine, 15.6 % in probable migraine, 5 % for tension-type headache (TTH) and 4% for probable TTH. Only 2.6% of migraineurs, 7.5% of probable migraine patients, 4.3% of tension-type headache and 0% of probable TTH received proper preventive treatment Conclusion: Primary headaches are common, debilitating conditions but a substantial proportion of those who might need prevention do not receive it. Patient education, public health initiatives in order to deliver migraine and other primary headaches treatment for the general population should be considered not only in Brazil, but worldwide.
id SBC_22bc44b7caaa5c82ac2fafa04d8f0fba
oai_identifier_str oai:ojs.pkp.sfu.ca:article/78
network_acronym_str SBC
network_name_str Revista Headache Medicine (Online)
repository_id_str
spelling The need for preventive therapy in primary headachesA necessidade da terapia preventiva nas cefaleias primáriasEnxaqueca; MigrâneaCefaleia do tipo tensionalPrevençãoEpidemiologiaMigraineTension-type headachePreventionepidemiologyIntroduction: Primary headaches are common conditions. In Brazil, the prevalence of migraine is 15.2%, tension-type headache 13% and chronic daily headache (CDH) 6.9%. Although frequent disorders a proportion of patients are undertreated. Patients patterns of headache care can trend toward acute medication only and those in need of prevention may not receive it. Objective: To estimate the rates of preventive treatment in primary headache sufferers. Methods: A telephone interview containing questions about headache and socio-demographic characteristics was applied to 3,848 people from 27 States of Brazil, in its five geographical regions. We considered MIDAS > 10 points as a marker for the need of preventive treatment. Patients were asked if they were taking any medication on a daily basis or any treatment to prevent headaches from happening. Subjects were divided into: 1. Those who responded positively for the question regarding preventive treatment regardless of the treatment type. 2. Those who responded positively for the question, but only medications or treatments studied for migraine prevention, labeled as "Correct treatment" 3. Those who responded positively for the question, but only medications or treatments from the prevention consensus (Brazilian Headache Society), labeled as "Consensus treatment" Results: In total, 12.8% of primary headache sufferers had MIDAS higher than 10, meeting criteria for prophylactic treatment, but only 8.4% of them reported it, 3.9% were using a right preventive treatment. The percentage of patients in need for prevention was 24.7% in migraine, 15.6 % in probable migraine, 5 % for tension-type headache (TTH) and 4% for probable TTH. Only 2.6% of migraineurs, 7.5% of probable migraine patients, 4.3% of tension-type headache and 0% of probable TTH received proper preventive treatment Conclusion: Primary headaches are common, debilitating conditions but a substantial proportion of those who might need prevention do not receive it. Patient education, public health initiatives in order to deliver migraine and other primary headaches treatment for the general population should be considered not only in Brazil, but worldwide.Introdução: As cefaleias primárias são condições comuns. No Brasil, a prevalência da migrânea é 15,2%, da cefaleia do tipo tensional é 13% e da cefaleia crônica diária (CDH), 6,9%. Apesar de tratar-se de doenças frequentes, uma proporção dos pacientes é subtratada. Os padrões de manejo da cefaleia dos pacientes podem levar ao uso exclusivo de medicamentos para o tratamento agudo das crises, e aqueles que necessitam de prevenção podem não recebê-la. Objetivo: Estimar as taxas de tratamento preventivo entre os indivíduos portadores de cefaleias primárias. Métodos: Uma entrevista telefônica contendo questões sobre cefaleia e características sociodemográficas foi aplicado a 3.848 pessoas de 27 estados brasileiros, nas suas cinco regiões demográficas. Nos consideramos um escore na escala MIDAS>10 pontos como um marcador da necessidade de tratamento preventivo. Os pacientes foram questionados quanto ao uso de qualquer medicação em um padrão diário ou de qualquer tratamento para prevenir a ocorrência de crises de cefaleia. Os indivíduos foram divididos em: 1. Aqueles que responderam positivamente à questão sobre o tratamento preventivo, independentemente do tipo de tratamento. 2. Aqueles que responderam positivamente à questão, mas apenas com medicamentos ou tratamentos estudados no tratamento preventivo da migrânea, rotulados como "tratamento correto". 3. Aqueles que responderam positivamente à questão, mas apenas com medicamentos ou tratamentos citados no consenso sobre tratamento profilático da Sociedade Brasileira de Cefaleia, rotulados como "tratamento consenso". Resultados: No total, 12,8% dos indivíduos acometidos por cefaleias primárias apresentaram MIDAS maior que 10, preenchendo critérios para tratamento profilático, porém apenas 8,4% deles relataram-no, apenas 3,9% destes utilizando um tratamento correto. A porcentagem dos pacientes necessitando de prevenção foi 24,7% na migrânea, 15,6% na migrânea provável, 5% na cefaleia do tipo tensional e 4% na cefaleia do tipo tensional provável. Apenas 2,6% dos migranosos, 7,5% pacientes com migrânea provável, 4,3% daqueles com cefaleia do tipo tensional e 0% daqueles com cefaleia do tipo tensional provável receberam tratamento preventivo adequado. Conclusão: As cefaleias primárias são condições debilitantes e comuns, porém uma proporção substancial daqueles que poderiam necessitar de prevenção não a recebem. Educação dos pacientes e iniciativas de saúde pública voltadas a proporcionar à população tratamento para a migrânea e outras cefaleias primárias devem ser consideradas não apenas no Brasil, mas globalmente.Sociedade Brasileira de Cefaleia2011-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/htmlhttps://headachemedicine.com.br/index.php/hm/article/view/7810.48208/HeadacheMed.2011.10Headache Medicine; Vol. 2 No. 2 (2011); 46-49Headache Medicine; v. 2 n. 2 (2011); 46-492763-6178reponame:Revista Headache Medicine (Online)instname:Sociedade Brasileira de Cefaleiainstacron:SBCenghttps://headachemedicine.com.br/index.php/hm/article/view/78/87https://headachemedicine.com.br/index.php/hm/article/view/78/377Copyright (c) 2011 Headache Medicinehttps://creativecommons.org/licenses/by/4.0/deed.ptinfo:eu-repo/semantics/openAccessPeres, Mario Fernando Prieto Amado, Daniel Krempel Gonçalves, André Leite Ribeiro, Reinaldo Pagura, Jorge Roberto Queiroz, Luiz Paulo de 2022-04-19T16:28:33Zoai:ojs.pkp.sfu.ca:article/78Revistahttp://headachemedicine.com.brPRIhttps://headachemedicine.com.br/index.php/hm/oaimmvalenca@yahoo.com.br | support@headachemedicine.com.br2763-61782178-7468opendoar:2022-04-19T16:28:33Revista Headache Medicine (Online) - Sociedade Brasileira de Cefaleiafalse
dc.title.none.fl_str_mv The need for preventive therapy in primary headaches
A necessidade da terapia preventiva nas cefaleias primárias
title The need for preventive therapy in primary headaches
spellingShingle The need for preventive therapy in primary headaches
Peres, Mario Fernando Prieto
Enxaqueca; Migrânea
Cefaleia do tipo tensional
Prevenção
Epidemiologia
Migraine
Tension-type headache
Prevention
epidemiology
title_short The need for preventive therapy in primary headaches
title_full The need for preventive therapy in primary headaches
title_fullStr The need for preventive therapy in primary headaches
title_full_unstemmed The need for preventive therapy in primary headaches
title_sort The need for preventive therapy in primary headaches
author Peres, Mario Fernando Prieto
author_facet Peres, Mario Fernando Prieto
Amado, Daniel Krempel
Gonçalves, André Leite
Ribeiro, Reinaldo
Pagura, Jorge Roberto
Queiroz, Luiz Paulo de
author_role author
author2 Amado, Daniel Krempel
Gonçalves, André Leite
Ribeiro, Reinaldo
Pagura, Jorge Roberto
Queiroz, Luiz Paulo de
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Peres, Mario Fernando Prieto
Amado, Daniel Krempel
Gonçalves, André Leite
Ribeiro, Reinaldo
Pagura, Jorge Roberto
Queiroz, Luiz Paulo de
dc.subject.por.fl_str_mv Enxaqueca; Migrânea
Cefaleia do tipo tensional
Prevenção
Epidemiologia
Migraine
Tension-type headache
Prevention
epidemiology
topic Enxaqueca; Migrânea
Cefaleia do tipo tensional
Prevenção
Epidemiologia
Migraine
Tension-type headache
Prevention
epidemiology
description Introduction: Primary headaches are common conditions. In Brazil, the prevalence of migraine is 15.2%, tension-type headache 13% and chronic daily headache (CDH) 6.9%. Although frequent disorders a proportion of patients are undertreated. Patients patterns of headache care can trend toward acute medication only and those in need of prevention may not receive it. Objective: To estimate the rates of preventive treatment in primary headache sufferers. Methods: A telephone interview containing questions about headache and socio-demographic characteristics was applied to 3,848 people from 27 States of Brazil, in its five geographical regions. We considered MIDAS > 10 points as a marker for the need of preventive treatment. Patients were asked if they were taking any medication on a daily basis or any treatment to prevent headaches from happening. Subjects were divided into: 1. Those who responded positively for the question regarding preventive treatment regardless of the treatment type. 2. Those who responded positively for the question, but only medications or treatments studied for migraine prevention, labeled as "Correct treatment" 3. Those who responded positively for the question, but only medications or treatments from the prevention consensus (Brazilian Headache Society), labeled as "Consensus treatment" Results: In total, 12.8% of primary headache sufferers had MIDAS higher than 10, meeting criteria for prophylactic treatment, but only 8.4% of them reported it, 3.9% were using a right preventive treatment. The percentage of patients in need for prevention was 24.7% in migraine, 15.6 % in probable migraine, 5 % for tension-type headache (TTH) and 4% for probable TTH. Only 2.6% of migraineurs, 7.5% of probable migraine patients, 4.3% of tension-type headache and 0% of probable TTH received proper preventive treatment Conclusion: Primary headaches are common, debilitating conditions but a substantial proportion of those who might need prevention do not receive it. Patient education, public health initiatives in order to deliver migraine and other primary headaches treatment for the general population should be considered not only in Brazil, but worldwide.
publishDate 2011
dc.date.none.fl_str_mv 2011-06-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://headachemedicine.com.br/index.php/hm/article/view/78
10.48208/HeadacheMed.2011.10
url https://headachemedicine.com.br/index.php/hm/article/view/78
identifier_str_mv 10.48208/HeadacheMed.2011.10
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://headachemedicine.com.br/index.php/hm/article/view/78/87
https://headachemedicine.com.br/index.php/hm/article/view/78/377
dc.rights.driver.fl_str_mv Copyright (c) 2011 Headache Medicine
https://creativecommons.org/licenses/by/4.0/deed.pt
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2011 Headache Medicine
https://creativecommons.org/licenses/by/4.0/deed.pt
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Cefaleia
publisher.none.fl_str_mv Sociedade Brasileira de Cefaleia
dc.source.none.fl_str_mv Headache Medicine; Vol. 2 No. 2 (2011); 46-49
Headache Medicine; v. 2 n. 2 (2011); 46-49
2763-6178
reponame:Revista Headache Medicine (Online)
instname:Sociedade Brasileira de Cefaleia
instacron:SBC
instname_str Sociedade Brasileira de Cefaleia
instacron_str SBC
institution SBC
reponame_str Revista Headache Medicine (Online)
collection Revista Headache Medicine (Online)
repository.name.fl_str_mv Revista Headache Medicine (Online) - Sociedade Brasileira de Cefaleia
repository.mail.fl_str_mv mmvalenca@yahoo.com.br | support@headachemedicine.com.br
_version_ 1838629558820012032